Shire PLC (ADR) (SHPG) Releases Earnings Results, Beats Expectations By $0.29 EPS

Shire PLC (ADR) (SHPG) reported quarterly earnings results on Tuesday, Aug-2-2016. The company said it had a profit of $3.38 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.29. Analysts had a consensus of $3.09. The company posted revenue of $2429.00 million in the period, compared to analysts expectations of $2275.68 million. The company’s revenue was up 55.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.63 EPS.

Many Wall Street Analysts have commented on Shire PLC (ADR). Company shares were Reiterated by Jefferies on Jun 3, 2016 to “Buy”, Firm has raised the Price Target to $ 262 from a previous price target of $223 .Stifel Initiated Shire PLC (ADR) on May 26, 2016 to “Buy”, Price Target of the shares are set at $230.Shire PLC (ADR) was Initiated by Liberum to “Buy” on May 6, 2016.

Shire PLC (ADR) opened for trading at $194.74 and hit $194.885 on the upside on Friday, eventually ending the session at $194.12, with a gain of 1.41% or 2.69 points. The heightened volatility saw the trading volume jump to 9,33,366 shares. Company has a market cap of $38,315 M.

Shire plc is a biopharmaceutical company. The Company along with its subsidiaries is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience Gastrointestinal (GI) Rare Diseases and Other therapeutic areas. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate) ADDERALL XR (mixed salts of a single-entity amphetamine) INTUNIV (extended release guanfacine) EQUASYM (methylphenidate hydrochloride) modified release (XL) BUCCOLAM LIALDA (mesalamine)/ MEZAVANT(mesalazine) PENTASA (mesalamine) RESOLOR (prucalopride) REPLAGAL (agalsidase alfa) VPRIV (velaglucerase alfa) FIRAZYR (icatibant) CINRYZE C1 esterase inhibitor (human) FOSRENOL (lanthanum carbonate) XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).

Shire PLC (ADR)

Leave a Reply

Shire PLC (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Shire PLC (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.